Skip to main content

Table 2 Combined efficacy and activity results

From: Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

Outcomes

Pts (RCTs)

HR/RR (95% CI)

p-value

Het. (p)

AD (%)

NNT

PFS

      

1st line

2,695 (3)

0.68 (0.56, 0.81)

0.0001

0.0001

8.4

12

2nd line

1,146 (2)

0.86 (0.69, 1.07)

0.19

0.14

-

-

OS

      

1st line

2,695 (3)

0.95 (0.85, 1.05)

0.338

0.64

-

-

2nd line

684 (1)

0.90 (0.71, 1.14)

0.38

1.00

-

-

ORR

      

1st-line

2,695 (3)

1.46 (1.21, 1.77)

< 0.0001

0.008

11.5

8-9

2nd-line

1,146 (2)

1.58 (1.00, 2.52)

0.05

0.092

8.4

12

  1. Pts: patients; RCTs: randomized clinical trials; HR: hazard ratio; RR: relative risk; CI: confidence intervals; Het.: heterogeneity; p: p-value; AD: absolute difference; NNT: number needed to treat.